Acute toxicity and patient‐reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer

Abstract

Introduction To confirm the feasibility of hypofractionated proton beam therapy (PBT), we compared the acute adverse event rates and International Prostate Symptom Score (IPSS) in prostate cancer patients treated with hypofractionated versus conventionally fractionated (2.0 Gy relative biological effectiveness (RBE)/fraction) PBT. Methods We reviewed 289 patients with prostate cancer, of whom 73, 100, and 116 patients were treated with 2.0, 2.5, and 3.0 Gy (RBE)/fraction, respectively. The endpoints were acute genitourinary and gastrointestinal toxicities and the IPSS, evaluated up to 6 months after PBT initiation. Results No significant differences were found in acute toxicity rates or the IPSS among the fractionation schedules. Diabetes mellitus, age, and androgen deprivation therapy were not identified as factors associated with the IPSS. Conclusion There were no significant differences in adverse events or quality of life among the three fractionation schedules early after PBT.

Does intensity‐modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score‐matched analysis

“…According to recent reports on hypofractionated radiotherapy (HFRT) for prostate cancer, there is no difference in genitourinary and gastrointestinal toxicity compared with conventionally fractionated radiotherapy. 22,23 Therefore, HFRT is expected to become a recognized approach in the future. Although there are no reports on the occurrence of secondary cancer after HFRT, the frequency of irradiation is related to increases in beam-on time, scattering, and the risk of bladder cancer; therefore, HFRT may help reduce the risk of secondary bladder cancer.…”

“…According to recent reports on hypofractionated radiotherapy (HFRT) for prostate cancer, there is no difference in genitourinary and gastrointestinal toxicity compared with conventionally fractionated radiotherapy 22,23 . Therefore, HFRT is expected to become a recognized approach in the future.…”

Moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial

“…While the safety and efficacy of hypofractionated RT have been confirmed for intensity-modulated radiation therapy using X-rays, there have been relatively few reports on hypofractionated PBT. We have been treating patients with 74–78 Gy relative biological effectiveness (RBE) in 37–39 fractions [ 8 ], and a single institutional phase II trial to confirm the safety and usefulness of a shortened PBT course of 70 Gy (RBE) in 28 fractions with a fractional dose of 2.5 Gy (RBE) was conducted [ 9 ]. In this study, we investigated the 5-year clinical outcomes of 100 patients registered onto the trial especially for feasibility.…”